From seropositivity to pathogenicity: causal evidence for autoantibodies in myasthenia gravis
- 1Department of Encephalopathy and Psychology, Shenzhen Traditional Chinese Medicine Hospital
- 2The Fourth Clinical Medical College, Guangzhou University of Chinese Medicine
Abstract
Autoantibody testing has expanded the serological spectrum of myasthenia gravis (MG), but detection of disease-associated immunoreactivity does not by itself establish direct pathogenicity. This Review examines how an MG-associated antibody moves from serological observation to mechanistic causality. We organize the evidence around three questions: whether the antibody signal is reproducible and biologically interpretable, whether circulating antibody can engage the native target and produce neuromuscular-junction dysfunction, and whether the resulting phenotype can be attributed to that antibody specificity. Acetylcholine receptor (AChR) and muscle-specific kinase (MuSK) antibodies provide mature causal benchmarks. Low-density lipoprotein receptor-related protein 4 (LRP4) illustrates established pathogenicity despite assay-dependent detection and an incompletely resolved balance between signaling interference, Fc-dependent effects, and local complement injury. Agrin has substantial biological and functional support, but independent sufficiency of human anti-agrin antibodies remains incompletely resolved. Cortactin provides a contrasting example in which repeated serological detection has not been linked convincingly to native target engagement or direct neuromuscular-junction dysfunction. ColQ, rapsyn, and collagen XIII remain unresolved for different reasons. Rather than assigning a numerical pathogenicity score, we identify the specific causal step that is missing for each antibody and match that uncertainty to the most informative experimental approach. This framework may improve interpretation of expanding antibody panels and help prioritize mechanistic studies that distinguish clinically useful biomarkers from directly pathogenic autoantibodies.
Related
- Anti-nephrin autoantibodies in podocytopathies: pathogenicity, assay discordance, and translation
- High risk of hypoxemic COVID-19 pneumonia in myasthenia gravis patients with type I IFN autoantibodies
- Ocular fluid biomarkers and anti-retinal autoantibodies in neovascular age-related macular degeneration: compartment-specific evidence and a provisional multidomain framework
- Pathogenicity of NUSAP1 Variants Is Defined by NMD‐Escape: Evidence From Two Novel Cases and Systematic Population‐Based Variant Analysis
- Evidence for maternal autoantibodies in the pathogenesis of preterm birth
BibTeX
@article{kong2026from,
title = {{From seropositivity to pathogenicity: causal evidence for autoantibodies in myasthenia gravis}},
author = {Fanxin Kong},
journal = {Frontiers in Immunology},
year = {2026},
month = oct,
doi = {10.3389/fimmu.2026.2008202},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.2008202/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - From seropositivity to pathogenicity: causal evidence for autoantibodies in myasthenia gravis
AU - Fanxin Kong
PY - 2026
DA - 2026/10/30
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.2008202
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.2008202/full
AB - Autoantibody testing has expanded the serological spectrum of myasthenia gravis (MG), but detection of disease-associated immunoreactivity does not by itself establish direct pathogenicity. This Review examines how an MG-associated antibody moves from serological observation to mechanistic causality. We organize the evidence around three questions: whether the antibody signal is reproducible and biologically interpretable, whether circulating antibody can engage the native target and produce neuromuscular-junction dysfunction, and whether the resulting phenotype can be attributed to that antibody specificity. Acetylcholine receptor (AChR) and muscle-specific kinase (MuSK) antibodies provide mature causal benchmarks. Low-density lipoprotein receptor-related protein 4 (LRP4) illustrates established pathogenicity despite assay-dependent detection and an incompletely resolved balance between signaling interference, Fc-dependent effects, and local complement injury. Agrin has substantial biological and functional support, but independent sufficiency of human anti-agrin antibodies remains incompletely resolved. Cortactin provides a contrasting example in which repeated serological detection has not been linked convincingly to native target engagement or direct neuromuscular-junction dysfunction. ColQ, rapsyn, and collagen XIII remain unresolved for different reasons. Rather than assigning a numerical pathogenicity score, we identify the specific causal step that is missing for each antibody and match that uncertainty to the most informative experimental approach. This framework may improve interpretation of expanding antibody panels and help prioritize mechanistic studies that distinguish clinically useful biomarkers from directly pathogenic autoantibodies.
SN - 1664-3224
ER -